HHT Europe is proud to launch S.T.R.E.A.M., a new international networking programme dedicated to improving care for people living with Hereditary Haemorrhagic Telangiectasia (HHT).

Severe, recurrent nosebleeds are the most common and disabling symptom of HHT, often leading to chronic anaemia, repeated hospital visits, and reduced quality of life. While sclerotherapy has proven to be a safe, effective, fast, and cost-efficient treatment, access to this technique is still limited in many European countries.

Through S.T.R.E.A.M., we aim to:

Bring together ENT specialists, researchers, and patient representatives from across Europe.

Provide training and knowledge exchange on sclerotherapy as an effective treatment for HHT-related nosebleeds.

Support clinicians and patient advocates from underrepresented regions to build local capacity.

Reduce inequalities in access to care and empower patients with more treatment options.

This initiative represents a key step in addressing unmet needs for HHT patients and building a stronger European network for rare vascular diseases.

📅 The programme will officially launch in [insert month/year Nov 2026 or Spring 2027]. Stay tuned for updates, registration details, and opportunities to get involved!